A Phase 4 interventional study of Faricimab Injection [Vabysmo] in Macular Degeneration, sponsored by Junyeop Lee. Recruiting at 5 sites in South Korea. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by Junyeop Lee · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing faricimab in Macular Degeneration — 6 open to participants now, 7 under way, 2 of them phase 3. faricimab · Macular Degeneration.
Among the 14 studies testing faricimab in Macular Degeneration, this one is the 7th largest by planned enrollment, is one of 3 that started in 2026, is one of 5 in phase 4, and was the 12th registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →6 of the 14 studies testing faricimab in Macular Degeneration are open now, in 4 countries. Recruiting first, the newest first:
Biobizkaia Health Research Institute · Sites in Spain
Ages 50+
Yeungnam University College of Medicine · Sites in Korea, Republic of
Ages 50+
Singapore National Eye Centre · Sites in Singapore
Ages 50+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 50+
Kim's Eye Hospital · Sites in Korea, Republic of
Ages 50+
By country, each count listing its studies:
faricimab: first FDA approval 2022 (VABYSMO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 4 · Phase 4 5
First in 2013; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 64 is above the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 57 across the 14 interventional studies. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 14 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Junyeop Lee as lead sponsor.
Junyeop Lee has 1 study filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing faricimab in Macular Degeneration, from their registry updates:
This tab as a report to print or save as PDF → With an account.
If the subject who has nAMD voluntarily agrees to participate in this clinical study by signing the informed consent form, screening assessments will be conducted within 4 weeks prior to the first dose of the investigational drug. During the screening visit, the eligibility of the subject will be assessed and one study eye will be selected. If both eyes are eligible, the eye with the worst best-corrected visual acuity (BCVA) at screening will be chosen. However, if the investigator determines that the other eye requires more urgent treatment for clinical reasons, that eye may be selected as the study eye.
After screening assessments and evaluation based on inclusion/exclusion criteria, eligible subjects will be enrolled. Vabysmo® 6 mg (0.05 mL) will be administered via intravitreal injection every 4 weeks (monthly) for a total of 4 doses during the initial loading period. After the loading dose, patients will undergo disease activity assessment based on imaging and visual acuity (VA) outcomes followed by the IP administration at Week 20. The treatment interval will be determined based on disease activity assessed at Week 20, depending on the results, the subsequent administration may be scheduled at Week 28 or Week 32, at the investigator's discretion. Thereafter, the dosing interval may be further adjusted in 4-week increments, either extended or shortened, according to imaging and visual outcomes.
Throughout the clinical study, patients will need to visit the study site at least 10 times, including the screening visit. The number of intravitreal injections administered will be 4 doses during the initial loading period and up to 5 doses during the treat-and-extend (T\&E) period (Weeks 20, 28, 36, 44, 52). Thus, the total number of injections during the study will range from a minimum of 7 to a maximum of 9 injections.
If the non-study eye also has nAMD, treatment with a locally approved therapy may be administered outside the scope of this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Ocular Conditions
Exclusion Criteria:
Ocular Conditions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Faricimab injection
Drug: Faricimab Injection [Vabysmo]
Faricimab Injection 6mg 0.05 cc
ANG-2 level in aqueous humour (AH)
Measurement of ANG-2 levels in aqueous humor (AH) and the change from baseline to week 20
Time frame: at Week 20 from baseline
Endothelial ANG-2 level in aqueous humour (AH)
Changes of endothelial ANG-2 level in aqueous humour (AH) at visits compared from baseline at Weeks 4, 12, 20 and 52
Time frame: At weeks 4, 12, 20 and 52 from baseline
BCVA measurement
Best Corrected Visual Acuity (BCVA) change from baseline at Weeks 20 and 52
Time frame: At weeks 20 and 52 from baseline
Subfoveal choroidal thickness
Change in subfoveal choroidal thickness at Weeks 20 and 52 compared to baseline (limited to PCV patients)
Time frame: At weeks 20 and 52 from baseline
Central subfield thickness (CST)
Central subfield thickness (CST) change from baseline at Weeks 20 and 52
Time frame: At weeks 20 and 52 from baseline
Intraretinal microaneurysms and vessel density of the deep capillary plexus
Change in the number of intraretinal microaneurysms and vessel density of the deep capillary plexus at Weeks 20 and 52 compared to baseline
Time frame: At weeks 20 and 52 from baseline
Area of peripheral non-perfusion in the retina
Change in the area of peripheral non-perfusion in the retina at Weeks 20 and 52 compared to baseline
Time frame: At weeks 20 and 52 from baseline
High improvement in vascular stabilization
Proportion of patients who achieved high improvement in vascular stabilization at Week 20 (defined as 2 or more score in Macular Neovascularization Stabilisation Scoring System Score range 0-4, higher scores mean a better outcome)
Time frame: from baseline at Weeks 20
Complete polyp regression
Proportion of subjects who experienced complete polyp regression at least once by Weeks 20 and 52 compared to baseline (limited to PCV patients)
Time frame: At weeks 20 and 52 from baseline
Polyp inactivation
Proportion of subjects who experienced polyp inactivation at least once by Weeks 20 and 52 compared to baseline (limited to PCV patients)
Time frame: At weeks 20 and 52 from baseline
Resolution of central Intraretinal fluid/Subretinal fluid(IRF/SRF)
Proportion of subjects with resolution of central IRF/SRF at Weeks 20 and 52 compared to baseline
Time frame: At weeks 20 and 52 from baseline
Vascular remodeling
Proportion of subjects who experiences vascular remodeling with changes in choroidal angiographic features at Weeks 20 and 52 compared to baseline
Time frame: At weeks 20 and 52 from baseline
Number of injections per patient
Mean number of injections per patient
Time frame: From baseline to Week 52(EOS)
Treatment interval
Proportion of subjects who achieved a treatment interval of ≥12 or 16 weeks at least once during the Treat \& Extend period
Time frame: From baseline to Week 52(EOS)
Maximum treatment interval
Distribution of maximum treatment interval during the Treat \& Extend period
Time frame: From baseline to Week 52(EOS)
AH biomarkers and imaging biomarkers
Correlation between AH biomarkers and imaging biomarkers
Time frame: From baseline to Week 52(EOS)
AH biomarkers and the maximum treatment interval
Correlation between AH biomarkers and the maximum treatment interval achieved during the T\&E period
Time frame: From baseline to Week 52(EOS)
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Apr 2028, 22 months after the start.
Of 45 phase 4 interventional studies under Macular Degeneration, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's planned 22 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Faricimab